# Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia

> **NCT05338190** · PHASE3 · RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 132 (estimated)

## Conditions studied

- Primary Immune Thrombocytopenia (ITP)

## Interventions

- **DRUG:** Combination of Rituximab with subcutaneous belimumab
- **DRUG:** Combination of Rituximab with subcutaneous placebo

## Key facts

- **NCT ID:** NCT05338190
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-14
- **Primary completion:** 2026-11-14
- **Final completion:** 2027-11-14
- **Target enrollment:** 132 (ESTIMATED)
- **Last updated:** 2023-09-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05338190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05338190, "Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT05338190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*